Synonyms that are in the dictionary are marked in green. Synonyms that are not in the dictionary are marked in red.
Antonyms that are in the dictionary are marked in green. Antonyms that are not in the dictionary are marked in red.
Oncternal Therapeutics has announced that it’s closing its Zilovertamab Phase 3 Study ZILO-301 and its Phase 1/2 Study CIRM-0001 study.
Source: https://investorplace.com/2023/04/why-is-oncternal-therapeutics-onct-stock-down-62-today/
Oncternal Therapeutics presently has a consensus price target of $5.33, suggesting a potential upside of 433.33%.